IntraCellular Therapies (ITCI)
(Delayed Data from NSDQ)
$75.52 USD
-0.29 (-0.38%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $75.46 -0.06 (-0.08%) 7:32 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Company Summary
New York-based Intra-Cellular Therapies is focused on the discovery, development and commercialization of novel small molecule drugs for treating neuropsychiatric and neurological disorders.
The company currently has one marketed drug in its portfolio, Caplyta (lumateperone 42 mg). The FDA approved Caplyta for the treatment of schizophrenia in adults in December 2019, while the commercial launch began in March 2020. Caplyta was approved for depressive episodes associated with bipolar I or II disorder in adults as monotherapy and adjunctive therapy with lithium or valproate in December 2021.
In April 2022, the company received FDA approval for two additional ...
Company Summary
New York-based Intra-Cellular Therapies is focused on the discovery, development and commercialization of novel small molecule drugs for treating neuropsychiatric and neurological disorders.
The company currently has one marketed drug in its portfolio, Caplyta (lumateperone 42 mg). The FDA approved Caplyta for the treatment of schizophrenia in adults in December 2019, while the commercial launch began in March 2020. Caplyta was approved for depressive episodes associated with bipolar I or II disorder in adults as monotherapy and adjunctive therapy with lithium or valproate in December 2021.
In April 2022, the company received FDA approval for two additional dosage strengths of Caplyta, 10.5 mg and 21 mg capsules, for special populations of patients. Consequently, these doses of Caplyta were commercially launched in August 2022.
Intra-cellular Therapeutics is also evaluating lumateperone in late-stage studies for major depressive disorder (MDD). It is also being developed as an adjunctive therapy to antidepressants for the treatment of MDD in phase III studies.
Intra-cellular Therapeutics is simultaneously developing its pipeline candidate ITI-1284-ODT-SL for multiple indications — the treatment of generalized anxiety disorder, psychosis in patients with Alzheimer's disease and agitation in patients with Alzheimer’s disease.
Other pipeline candidates include lenrispodun (ITI-214) for Parkinson’s disease (PD) and ITI-333 as a potential treatment for substance use disorders, pain and psychiatric comorbidities including depression and anxiety.
With only one marketed product in its portfolio, Intra-Cellular Therapeutics generates revenues from Caplyta sales. In 2023, the company generated $464.4 million in total revenues compared with $250.3 million in 2022.
General Information
IntraCellular Therapies Inc
430 EAST 29TH STREET
NEW YORK, NY 10016
Phone: 646-440-9333
Fax: 646-440-9334
Web: http://www.intracellulartherapies.com
Email: ir@itci-inc.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/7/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.17 |
Current Year EPS Consensus Estimate | -0.59 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/7/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 75.81 |
52 Week High | 84.89 |
52 Week Low | 45.50 |
Beta | 1.00 |
20 Day Moving Average | 478,393.81 |
Target Price Consensus | 96.13 |
4 Week | 1.77 |
12 Week | 11.50 |
YTD | 5.85 |
4 Week | -0.04 |
12 Week | 6.75 |
YTD | -11.71 |
Shares Outstanding (millions) | 105.67 |
Market Capitalization (millions) | 8,010.61 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 64.44% |
vs. Previous Quarter | 0.00% |
vs. Previous Year | 45.67% |
vs. Previous Quarter | 11.41% |
Price/Book | 6.99 |
Price/Cash Flow | NA |
Price / Sales | 14.19 |
6/30/24 | -11.48 |
3/31/24 | -18.49 |
12/31/23 | -23.02 |
6/30/24 | -9.60 |
3/31/24 | -15.26 |
12/31/23 | -19.39 |
6/30/24 | 7.81 |
3/31/24 | 5.12 |
12/31/23 | 5.41 |
6/30/24 | 7.69 |
3/31/24 | 5.00 |
12/31/23 | 5.31 |
6/30/24 | -14.93 |
3/31/24 | -21.57 |
12/31/23 | -30.08 |
6/30/24 | -14.93 |
3/31/24 | -21.57 |
12/31/23 | -30.08 |
6/30/24 | -14.77 |
3/31/24 | -21.38 |
12/31/23 | -29.94 |
6/30/24 | 10.84 |
3/31/24 | 6.19 |
12/31/23 | 6.15 |
6/30/24 | 1.81 |
3/31/24 | 1.31 |
12/31/23 | 1.08 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |